80 programming-"the"-"DAAD"-"EURAXESS"-"IMPRS-ML"-"O.P"-"UCL"-"P" positions at Ulster University
Sort by
Refine Your Search
-
supported by PEACEPLUS, a programme managed by the Special EU Programmes Body (SEUPB) involving a range of partner organisations. NWCAM2 is an initiative seeking to help small and medium sized enterprises
-
. It aligns with the Programme for Government 2024–2027 and positions the region as a leader in equitable, multilingual governance. The project’s outcomes—evidence-based policy recommendations
-
waiting lists, support and optimise programme uptake and outcomes, using observational questionnaires and exit interviews. Methods An in-depth analysis of existing Pulmonary Rehabilitation programmes in
-
food intake is reduced and the signalling pathways of the appetite centres of the brain involved. This PhD programme will evaluate changes in appetitive and consummatory behaviours in individuals
-
residency criteria which requires that they have lived in the EEA, Switzerland, the UK or Gibraltar for at least the three years preceding the start date of the research degree programme. Applicants who
-
residency criteria which requires that they have lived in the EEA, Switzerland, the UK or Gibraltar for at least the three years preceding the start date of the research degree programme. Applicants who
-
residency criteria which requires that they have lived in the EEA, Switzerland, the UK or Gibraltar for at least the three years preceding the start date of the research degree programme. Applicants who
-
by 2050, to mitigate against the effects of climate change. Key areas identified by the Department for the Economy’s ‘Energy Strategy’ and ‘Energy Action Plan 2025’ for innovation include expanding
-
and Health Sciences Sectoral Action Plan, which emphasise high-impact innovation, translational research, and the development of precision medicine capabilities in Northern Ireland. The outcomes will
-
Summary Applicants are invited to undertake a 3 year PhD program in partnership with a global leader in blood- and cell-based therapies (Terumo Blood and Cell Technologies Ltd). This opportunity